[{"orgOrder":0,"company":"Imugene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"Azercabtagene Zapreleucel","moa":"CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Imugene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Imugene \/ Undisclosed"},{"orgOrder":0,"company":"Imugene","sponsor":"MaxCyte","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Azercabtagene Zapreleucel","moa":"||CD19","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Imugene \/ MaxCyte","highestDevelopmentStatusID":"7","companyTruncated":"Imugene \/ MaxCyte"},{"orgOrder":0,"company":"Amplia Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"AMP945","moa":"FAK","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Amplia Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amplia Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Amplia Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Prescient Therapeutics","sponsor":"National Cancer Institute","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Cyclophosphamide","moa":"DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prescient Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prescient Therapeutics \/ National Cancer Institute","highestDevelopmentStatusID":"7","companyTruncated":"Prescient Therapeutics \/ National Cancer Institute"},{"orgOrder":0,"company":"EnGeneIC","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody-drug Conjugate","year":"2020","type":"Inapplicable","leadProduct":"E-EDV-D682","moa":"||DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EnGeneIC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"EnGeneIC \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"EnGeneIC \/ Undisclosed"},{"orgOrder":0,"company":"EnGeneIC","sponsor":"Herbert Irving Comprehensive Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"E-EDV-D682","moa":"DNA topoisomerase II","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"EnGeneIC","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EnGeneIC \/ Herbert Irving Comprehensive Cancer Center","highestDevelopmentStatusID":"7","companyTruncated":"EnGeneIC \/ Herbert Irving Comprehensive Cancer Center"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"64Cu-SAR-bisPSMA","moa":"||Glutamate carboxypeptidase II (GCPII)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clarity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"64Cu-SAR-bisPSMA","moa":"||Glutamate carboxypeptidase II (GCPII)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clarity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"64-Cu SAR Bombesin","moa":"||GRPr","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Imugene","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2016","type":"Inapplicable","leadProduct":"IMU-131","moa":"HER2\/Neu receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Imugene","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Imugene \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Imugene \/ Undisclosed"},{"orgOrder":0,"company":"AdvanCell","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"212-Pb ADVC001","moa":"Ionising radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AdvanCell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AdvanCell \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"AdvanCell \/ Undisclosed"},{"orgOrder":0,"company":"AdvanCell","sponsor":"SV Health Investors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2025","type":"Series C Financing","leadProduct":"212-Pb ADVC001","moa":"Ionising radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AdvanCell","amount2":0.11,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Injection","sponsorNew":"AdvanCell \/ SV Health Investors","highestDevelopmentStatusID":"7","companyTruncated":"AdvanCell \/ SV Health Investors"},{"orgOrder":0,"company":"AdvanCell","sponsor":"Medical Research Future Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2025","type":"Funding","leadProduct":"212-Pb ADVC001","moa":"Ionising radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AdvanCell","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"AdvanCell \/ Medical Research Future Fund","highestDevelopmentStatusID":"7","companyTruncated":"AdvanCell \/ Medical Research Future Fund"},{"orgOrder":0,"company":"AdvanCell","sponsor":"Point Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2023","type":"Collaboration","leadProduct":"212-Pb ADVC001","moa":"Ionising radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AdvanCell","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"AdvanCell \/ Point Biopharma","highestDevelopmentStatusID":"7","companyTruncated":"AdvanCell \/ Point Biopharma"},{"orgOrder":0,"company":"AdvanCell","sponsor":"Morningside Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2022","type":"Series B Financing","leadProduct":"212-Pb ADVC001","moa":"Ionising radiation","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"AdvanCell","amount2":0.02,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Injection","sponsorNew":"AdvanCell \/ Morningside Ventures","highestDevelopmentStatusID":"7","companyTruncated":"AdvanCell \/ Morningside Ventures"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"131-I Phenylalanine","moa":"||LAT-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Telix Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Telix Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2021","type":"Inapplicable","leadProduct":"131-I Phenylalanine","moa":"LAT-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Telix Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Telix Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"131-I Phenylalanine","moa":"LAT-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Telix Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Telix Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Telix Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2022","type":"Inapplicable","leadProduct":"131-I Phenylalanine","moa":"LAT-1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Telix Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Telix Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Telix Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CNA3103","moa":"LGR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Carina Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Carina Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CNA3103","moa":"LGR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Carina Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Carina Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"CNA3103","moa":"LGR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Carina Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Carina Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Carina Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CNA3103","moa":"LGR5","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Carina Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Carina Biotech \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Carina Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Syntara Limited","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"PXS-5505","moa":"Pan-LOX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syntara Limited","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syntara Limited \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Syntara Limited \/ Undisclosed"},{"orgOrder":0,"company":"Pharmaxis","sponsor":"University of Rochester Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"PXS-5505","moa":"||Pan-LOX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pharmaxis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmaxis \/ University of Rochester Medical Center","highestDevelopmentStatusID":"7","companyTruncated":"Pharmaxis \/ University of Rochester Medical Center"},{"orgOrder":0,"company":"Pharmaxis","sponsor":"Parexel Biotech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"PXS-5505","moa":"Pan-LOX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pharmaxis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmaxis \/ Parexel Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Pharmaxis \/ Parexel Biotech"},{"orgOrder":0,"company":"Pharmaxis","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"PXS-5505","moa":"Pan-LOX","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Pharmaxis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Pharmaxis \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Pharmaxis \/ Undisclosed"},{"orgOrder":0,"company":"Prescient Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"PTX-200","moa":"RAC-alpha serine\/threonine-protein kinase (AKT1)","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prescient Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prescient Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Prescient Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Prescient Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Triciribine","moa":"Serine\/threonine-protein kinase AKT","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Prescient Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Prescient Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Prescient Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Cardinal Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2021","type":"Agreement","leadProduct":"67-Cu MeCOSar-Tyr3-octreotate","moa":"SST2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clarity Pharmaceuticals \/ Cardinal Health","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Cardinal Health"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"64-Cu MeCOSar-Tyr3-octreotate","moa":"||SST2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Clarity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"64-Cu SARTATE","moa":"SSTR2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"FivepHusion","sponsor":"Syneos Health","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2023","type":"Collaboration","leadProduct":"Fluorouracil","moa":"||Thymidylate synthase | RNA | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FivepHusion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FivepHusion \/ Syneos Health","highestDevelopmentStatusID":"7","companyTruncated":"FivepHusion \/ Syneos Health"},{"orgOrder":0,"company":"FivepHusion","sponsor":"Allarity Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cytotoxic Drug","year":"2023","type":"Collaboration","leadProduct":"Fluorouracil","moa":"||Thymidylate synthase | RNA | DNA","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"FivepHusion","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"FivepHusion \/ Allarity Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"FivepHusion \/ Allarity Therapeutics"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Idronoxil","moa":"TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Noxopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm \/ Undisclosed"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Idronoxil","moa":"TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Noxopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm \/ Undisclosed"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Idronoxil","moa":"TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Noxopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm \/ Undisclosed"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Idronoxil","moa":"||TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noxopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm \/ Undisclosed"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Idronoxil","moa":"||TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noxopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm \/ Undisclosed"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Idronoxil","moa":"TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noxopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm \/ Undisclosed"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Idronoxil","moa":"TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noxopharm \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm \/ Undisclosed"},{"orgOrder":0,"company":"Noxopharm","sponsor":"Genesiscare","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2020","type":"Agreement","leadProduct":"Idronoxil","moa":"TOP2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Noxopharm","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Noxopharm \/ Genesiscare","highestDevelopmentStatusID":"7","companyTruncated":"Noxopharm \/ Genesiscare"},{"orgOrder":0,"company":"Rhine Pharma","sponsor":"Telix Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Miscellaneous","year":"2024","type":"Demerger","leadProduct":"188-Re PSMA","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Rhine Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rhine Pharma \/ Telix Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"Rhine Pharma \/ Telix Pharmaceuticals"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Peptide, Unconjugated","year":"2023","type":"Inapplicable","leadProduct":"64-Cu SAR-BBN","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Clarity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2019","type":"Inapplicable","leadProduct":"67-Cu SARTATE","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"67-Cu SARTATE","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"67-Cu SARTATE","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2020","type":"Inapplicable","leadProduct":"67-Cu SARTATE","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"NorthStar Medical Radioisotopes","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2023","type":"Inapplicable","leadProduct":"67-Cu SARTATE","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ NorthStar Medical Radioisotopes","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ NorthStar Medical Radioisotopes"},{"orgOrder":0,"company":"Clarity Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2020","type":"Financing","leadProduct":"67-Cu SARTATE","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Clarity Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Injection","sponsorNew":"Clarity Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Clarity Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Chimeric Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"CHM-2101 CAR-T Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Chimeric Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Chimeric Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Chimeric Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Filamon","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Kesonotide","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Filamon","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Filamon \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Filamon \/ Undisclosed"},{"orgOrder":0,"company":"Radiopharm Theranostics","sponsor":"Medpace, Inc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Radiolabeled Compound","year":"2025","type":"Inapplicable","leadProduct":"177-Lu BetaBart","moa":"CD276","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Radiopharm Theranostics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Radiopharm Theranostics \/ Medpace, Inc","highestDevelopmentStatusID":"7","companyTruncated":"Radiopharm Theranostics \/ Medpace, Inc"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
